Poging GOUD - Vrij
A tariff pill: Why India, US and China hold the key to affordable medicines
The Business Guardian
|July 18, 2025
Donald Trump is back on the campaign trail, promising to slash drug prices. "I will get drug prices way down," he declared this year.
Few Americans would argue with the urgency of affordable medicine, especially as health-care costs continue to burden families and government programs alike.
Yet, in April, President Trump imposed a sweeping 10% tariff on all imports, including pharmaceuticals and medical supplies, under the International Emergency Economic Powers Act. Simultaneously, his administration launched a national security investigation under Section 232 that could impose tariffs of up to 25% on finished drug products and active pharmaceutical ingredients (APIs). Generics, the backbone of affordable American medicine, are squarely in the crosshairs of these trade policies.
At first glance, tariffs appear as a tough stance against foreign suppliers, a way to protect American jobs and industries. But the reality is far more complex and, frankly, dangerous. These tariffs threaten to destabilize a drug supply chain that millions of Americans rely on daily and leave the United States far more exposed to future shocks.
India plays an outsized role in America's generic drug supply. According to the U.S. Food and Drug Administration (FDA), Indian manufacturers supply roughly 40% of the generics consumed in the United States. From antibiotics to blood pressure medicines to cancer therapies, these affordable drugs keep health care accessible for millions of patients and help contain the enormous costs borne by Medicare and Medicaid.
But India's generic industry has a critical vulnerability: it remains heavily dependent on China for its raw ingredients. Approximately 70% of the active pharmaceutical ingredients (APIs)—the chemical building blocks of all medicines—used by Indian generic producers are imported from China, according to India's Ministry of Commerce. This dependency is a geopolitical and economic risk waiting to materialize.
Dit verhaal komt uit de July 18, 2025-editie van The Business Guardian.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN The Business Guardian
The Business Guardian
DIAMETRICALLY OPPOSITE POLARITIES: EMBRACING LIFE'S DUAL NATURE
Life is a continuous interplay of opposites. Day and night, joy and sorrow, love and fear, creation and destruction—all exist in a delicate balance.
2 mins
December 01, 2025
The Business Guardian
Cinema sans songs?
'No poet, no artist of any art, has his complete meaning alone.
8 mins
December 01, 2025
The Business Guardian
Jio continues strongest growth in mobile and broadband users in Oct: TRAI
Reliance Jio stayed at the front of India’s telecom race in October 2025, adding more users than any other operator across major mobile and broadband categories, according to new data from the Telecom Regulatory Authority of India (TRAI).
1 mins
December 01, 2025
The Business Guardian
Gold could retest record highs as traders eye Powell's speech, RBI policy: Analysts
Gold prices are poised to remain firm and could edge closer to record highs next week as investors await key US data, Federal Reserve Chair Jerome Powell's speech and the Reserve Bank of India’s policy decision, analysts said.
2 mins
December 01, 2025
The Business Guardian
Mindful moments: When the stillness speaks
In a world dominated by speed and constant stimulation, cultivating a meditative state is essential.
2 mins
December 01, 2025
The Business Guardian
BHOPAL AT 41: THE NIGHT ENDED, BUT THE TRAGEDY INDUSTRY CONTINUES
Forty-one years after the Bhopal Gas Tragedy, India continues its yearly act of remembrance.
4 mins
December 01, 2025
The Business Guardian
Drug Resistance Threat Deepens; National and Global Experts Convene at Amrita Hospital's AMR NEXT 2025
With antimicrobial resistance (AMR) rising at an alarming pace and threatening to erode decades of medical progress, top leaders from government, public health, academia, biotechnology, and international agencies will gather at Amrita Hospital, Faridabad for AMR NEXT 2025 - “Transformative Strategies to Tackle Antimicrobial Resistance: For a Safer Tomorrow.”
1 min
December 01, 2025
The Business Guardian
Wakefit to float IPO on Dec 8; eyes Rs 1,400 cr
Home and furnishings company Wakefit Innovations Ltd is gearing up to launch its initial public offering (IPO) on December 8 to raise around Rs 1,400 crore.
2 mins
December 01, 2025
The Business Guardian
International Conference on the Preservation of Rural Buddhist Heritage Charts
The International Conference on the Preservation of Rural Buddhist Heritage, organized by the Indian Trust for Rural Heritage and Development (ITRHD), concluded today at the Dr. Ambedkar International Centre (DAIC), New Delhi, with the adoption of the Delhi Declaration—a landmark roadmap for safeguarding and revitalizing India’s rural Buddhist heritage.
1 min
December 01, 2025
The Business Guardian
'FY26 GDP growth revised to 7.6%, MSME credit set to cross Rs 6 lakh cr'
India's economy expanded 8.2 per cent in Q2 FY26, the highest in six quarters, backed by strong growth in manufacturing, construction, and services, according to the latest SBI Research Ecowrap report.
2 mins
December 01, 2025
Listen
Translate
Change font size

